AGI has developed specialized preclinical platforms to evaluate therapies targeting autoimmune and rare diseases, areas where translational models are limited and unmet need is high. Our capabilities span induced and naturally occurring disease models that capture the complexity of human immune dysfunction, allowing sponsors to evaluate therapeutic efficacy in clinically relevant systems. Studies include comprehensive immunological monitoring, histopathology, cytokine profiling, and functional outcome assessments, delivering high-resolution data that captures both efficacy and safety. We support programs developing monoclonal antibodies, small molecules, gene therapies, and novel biologics, tailoring endpoints to align with FDA expectations for orphan and autoimmune indications. By leveraging rare disease models that accurately mimic human disease progression, we provide translationally relevant datasets that reduce risk and accelerate advancement into the clinic.

 

Our GLP-compliant infrastructure, combined with the ability to integrate exploratory research with regulatory-grade studies, ensures that sponsors receive both flexibility and rigor. Through these capabilities, Alpha Genesis plays a vital role in enabling new therapies for patient populations with few existing options, advancing science while addressing some of the most challenging conditions in modern medicine and improving long-term outcomes for underserved groups.